Mortality Benefit With Prasugrel in the TRITON–TIMI 38 Coronary Artery Bypass Grafting Cohort Risk-Adjusted Retrospective Data Analysis by Smith, Peter K. et al.
L
E
S
U
a
S
E
C
h
t
2
Journal of the American College of Cardiology Vol. 60, No. 5, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
PCardiac Surgery
Mortality Benefit With Prasugrel in the
TRITON–TIMI 38 Coronary Artery Bypass Grafting Cohort
Risk-Adjusted Retrospective Data Analysis
Peter K. Smith, MD,* Lawrence T. Goodnough, MD,† Jerrold H. Levy, MD,‡ Robert S. Poston, MD,§
Mary A. Short, MSN, Govinda J. Weerakkody, PHD, LeRoy A. LeNarz, MD
Durham, North Carolina; Stanford, California; Atlanta, Georgia; Tucson, Arizona; and Indianapolis, Indiana
Objectives The objective of this study was to characterize the bleeding, transfusion, and other outcomes of patients related
to the timing of prasugrel or clopidogrel withdrawal before coronary artery bypass grafting (CABG).
Background There is little evidence to guide clinical decision making regarding the use of prasugrel in patients who may
need urgent or emergency CABG. Experience with performing CABG in the presence of clopidogrel has raised
concern about perioperative bleeding complications that are unresolved.
Methods A subset of the TRITON–TIMI 38 study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing
Platelet Inhibition with Prasugrel–Thrombolysis In Myocardial Infarction 38), in which patients with acute coro-
nary syndrome were randomized to treatment with aspirin and either clopidogrel or prasugrel, underwent iso-
lated CABG (N  346). A supplemental case report form was designed and administered, and the data com-
bined with the existing TRITON–TIMI 38 database. Baseline imbalances were corrected for using elements of the
European System for Cardiac Operative Risk Evaluation and The Society of Thoracic Surgeons predictive
algorithm.
Results A significantly higher mean 12-h chest tube blood loss (655  580 ml vs. 503  378 ml; p  0.050) was ob-
served with prasugrel compared with clopidogrel, without significant differences in red blood cell transfusion
(2.1 U vs. 1.7 U; p  0.442) or the total donor exposure (4.4 U vs. 3.0 U; p  0.463). All-cause mortality was
significantly reduced with prasugrel (2.31%) compared with 8.67% with clopidogrel (adjusted odds ratio: 0.26;
p  0.025).
Conclusions Despite an increase in observed bleeding, platelet transfusion, and surgical re-exploration for bleeding, prasugrel
was associated with a lower rate of death after CABG compared with clopidogrel. (A Comparison of Prasugrel
[CS-747] and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary In-
tervention; NCT00097591) (J Am Coll Cardiol 2012;60:388–96) © 2012 by the American College of Cardiol-
ogy Foundation
ublished by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.030Coronary artery bypass grafting (CABG) is one of the most
frequently performed cardiac surgical procedures and affects
the management of one-quarter of a million patients each
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012, accepted March 13, 2012.year. The benefit of antiplatelet therapy early in the process
of acute coronary syndrome (ACS) is well documented but
is less certain when CABG may be the preferred treatment
option (1–3). Studies have reported a substantial increased
risk of CABG-related major bleeding as a result of concur-
rent antiplatelet (thienopyridine) therapy (4–8). Others
have reported that the relationship between timing of
thienopyridine withdrawal preoperatively and CABG is
only modest and variable (9–12). Further complicating the
issue is that, despite the potential for surgical bleeding
problems, several studies suggest that there may be an
ischemic and/or mortality benefit with some degree of
platelet inhibition in patients undergoing CABG (3–8). In
TRITON–TIMI 38 (Trial to Assess Improvement in Ther-
apeutic Outcomes by Optimizing Platelet Inhibition with
Prasugrel–Thrombolysis In Myocardial Infarction 38), pra-
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July 31, 2012:388–96 The TRITON–TIMI 38 CABG Cohortsugrel was associated with an increased risk of CABG-
related bleeding compared to clopidogrel (13.4% vs. 3.2%;
p  0.001) when adjudicated by using the TIMI criteria (6).
However, a trend toward reduction in CABG mortality in those
patients randomized to receive prasugrel treatment was noted as a
potential offsetting benefit among the patients undergoing
CABG (13). The trial design was not adequate to correct for
baseline imbalances in patients who were not randomly
assigned to undergo CABG, and the bleeding outcome data
were insufficient to accurately characterize surgical bleeding,
the known risk factors associated with bleeding and the
complications related to bleeding. Accordingly, the cur-
rent study uses the analysis of additional data, which were
acquired to expand the prior database and to allow
characterization of perioperative bleeding (i.e., to allow
further analysis of type, extent, other bleeding risk
factors, and management of bleeding) as potentially
related to the timing of thienopyridine withdrawal before
CABG. Supplementary data were also acquired to facil-
itate generation of risk-adjustment models for CABG
(European System for Cardiac Operative Risk Evaluation
score [EuroSCORE] [14] and The Society of Thoracic
Surgeons [STS] score [15]). These models were then
used to estimate preoperative mortality risk for patients
who underwent CABG subsequent to enrollment and
treatment with either prasugrel or clopidogrel in the
TRITON–TIMI 38 study. The goal of the current analysis
was to provide additional information to facilitate the
assessment of risk benefit with respect to the pre-operative
administration of thienopyridines.
Methods
The study design and principal results from the pivotal
phase III TRITON–TIMI 38 trial have been published
(6,16). Briefly, 13,608 patients with ACS to be managed
with percutaneous coronary intervention (PCI) were ran-
domized to receive a loading dose (60 mg of prasugrel or
300 mg of clopidogrel) followed by a daily maintenance
dose (10 mg of prasugrel or 75 mg of clopidogrel) for up to
15 months in combination with aspirin (6). The primary
efficacy endpoint was the time of first occurrence of any
element of the composite of cardiovascular (CV) death,
nonfatal myocardial infarction (MI), or nonfatal stroke.
Safety was assessed by using TIMI bleeding criteria (16) and
based on a fall in hemoglobin levels or intracranial hemor-
rhage versus actual measurement of chest tube output.
A supplemental case report form was developed to collect
additional data from patients in TRITON–TIMI 38 who
underwent CABG at any time point during the study. The
data collection was designed to characterize the relationship
of the withdrawal of thienopyridine before CABG to
cumulative chest tube drainage and transfusions and to
collect additional clinical risk factors for bleeding and
adverse outcomes. An analysis plan was prospectively devel-
oped to include recognized risk-adjustment methods for wCABG (EuroSCORE and STS
scoring) mortality. Supplemen-
tary retrospective data collection
was conducted by using chart
review and was limited to the
information captured during the
patient’s study participation.
This review was performed
with the acknowledgment or ap-
proval of the ethics committee
and regulatory board or as re-
quired by local regulations. The
data were independently ana-
lyzed by a statistician from Duke
University Medical Center. The
corresponding author had full ac-
cess to the data in the study.
Population. The initial study
population included the 485 pa-
tients who underwent CABG
with or without concomitant car-
diac procedures during their par-
ticipation in the TRITON–TIMI 38 study from November
2004 to January of 2007. In 36 patients, a supplementary
case report form could not be obtained. Two of the 36 (1
randomized to receive prasugrel but did not receive study
drug; 1 randomized to receive clopidogrel and received drug
before the procedure) failed to survive surgery and were
included; the remaining 34 patients (11 in the prasugrel
group and 23 in the clopidogrel group) with missing
supplemental data were excluded, leaving 451 patients.
Three additional patients were excluded due to an inability
to determine the type of operative procedure performed, for
a balance of 448 patients. Thus, the EuroSCORE and STS
risk-adjusted predicted mortality was considered calculable
for 446 of these 448 patients. The cohort of 448 included all
deaths and all but 2 patients who were classified in the
TRITON–TIMI 38 trial as having had TIMI major/minor
bleeds (1 prasugrel-treated and 1 clopidogrel-treated
patient).
The cohort of 448 patients was heterogeneous and
included patients with major concomitant cardiac proce-
dures in addition to CABG (n  26), open-label use of
antiplatelet therapy before the procedure (n  20), and
patients who did not receive study medication (n  56).
herefore, the key population of interest was further refined
o include only the cohort of 346 patients who underwent
solated CABG and received study drug before procedure.
afety and mortality analysis. Selection bias may be in-
roduced due to the nonrandomized nature of the decision
o perform CABG and the timing of study drug withdrawal;
his could confound the comparison between prasugrel and
lopidogrel. Thus, predicted probability of periprocedural
ortality was used to adjust for potential imbalances and to
alidate comparisons. The predicted probability of mortality
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CABG  coronary artery
bypass grafting
CI  confidence interval
COPD  chronic
obstructive pulmonary
disease
CV  cardiovascular
EuroSCORE  European
System for Cardiac
Operative Risk Evaluation
score
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
STS  Society of Thoracic
Surgeonsas calculated using EuroSCORE (14) or STS score (15)
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STS score based on risk factors, any missing values were
considered as absence of that risk factor as recommended by
the STS National Cardiac Database Committee. The pri-
mary safety endpoint was cumulative chest tube output in
the first 12 post-operative hours after CABG. Key second-
ary safety endpoints included incidence of surgical re-
exploration for bleeding, mortality within 30 days after
CABG, occurrence of CV death, nonfatal MI, or nonfatal
stroke within 30 days after CABG and total donor exposure.
No adjustment was made for the possible selection bias in
comparison of bleeding risk between prasugrel and clopi-
dogrel due to the absence of a widely accepted measure for
predicted risk of CABG-related bleeding.
Statistical methods. Major surgical characteristics and
mortality were analyzed for isolated CABG and for major
cardiac procedures in addition to the CABG procedure
(designated as CABG). Statistical analyses and summaries
are presented for isolated CABG procedures. Surgical
characteristics, medical history, preoperative and postoper-
ative (collected in hospital until discharge or on readmission
within 30 days of CABG) state, hemodynamic and cathe-
terization information, concomitant medication use during
the periprocedural period, and the predicted probability of
mortality at the time of CABG were summarized for each
study drug. Statistical comparisons of these characteristics
between prasugrel and clopidogrel were guided according to
the data type: comparison of distributions of nominal data
Figure 1 Patient Flow
CABG patients received additional cardiac surgical procedures. CABG  coronarby using the Cochran-Mantel-Haenszel general association
test, comparison of medians by using the Cochran-Mantel-
Haenszel row mean score test for ordinal data, comparison
of medians by using the Kruskal-Wallis test, and compari-
son of means by using the 2-sample t test or analysis of
variance, as appropriate, for interval scale data.
Average cumulative chest tube blood loss at 12 h after
CABG was compared by using the Kruskal-Wallis test.
Kaplan-Meier methods were used for estimating the time
profiles of cumulative hazard. A Cox proportional hazards
model was used for estimating the unadjusted hazard ratio for
prasugrel versus clopidogrel. Comparison between time pro-
files were conducted by using the log-rank test. Comparison of
the risk of all-cause death, CV death, all-cause death through
30 days from CABG, and in-hospital death between prasugrel
and clopidogrel was performed using logistic regression anal-
ysis, and the predicted probability of periprocedural mortality
was included as a covariate. Separate analyses were performed
by using the STS predicted mortality score and the Euro-
SCORE as covariates and produced similar results.
All analyses were conducted by using SAS version 9.1
(SAS Institute, Inc., Cary, North Carolina).
Results
Patients. A patient flow diagram (including deaths for each
group) for the retrospective analysis is illustrated in Figure 1.
Patients with procedures in addition to CABG (e.g., con-
y bypass grafting; N  number of patients.y arter
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July 31, 2012:388–96 The TRITON–TIMI 38 CABG Cohortcomitant valve repair or replacement, aortic surgery, ven-
tricular septal defect repair) were designated as CABG
(n  26), leaving the majority of patients in the isolated
ABG group (n  422). The CABG group required
onger cardiopulmonary bypass time (83  38 min for
solated CABG compared with 140 46 min for CABG)
nd had increased mortality (5.5% for isolated CABG
ompared with 30.8% for CABG). Due to the heteroge-
eity of the CABG group and limited ability to risk-
djust for the complex procedures, the main analyses fo-
used on the isolated CABG group and were limited to
hose who received study drug before CABG without
xposure to open-label clopidogrel before CABG.
There was no difference in time from randomization to
solated CABG procedure between treatment groups (Fig. 2).
emographic characteristics and medical history for the
solated CABG group are summarized in Table 1. Pre-
perative and procedural characteristics are summarized in
able 2. Eight-five percent of the procedures were elective,
onsistent with the majority of them being performed 90
ays after the enrolling unstable angina event. There was a
ignificantly higher percentage of chronic obstructive pul-
onary disease (COPD) and on-pump procedures in the
lopidogrel cohort. There was no evidence of interaction
etween the decision to perform off-pump CABG and the
resence of COPD, and no association of mortality with the
hoice of on-pump compared with off-pump CABG per-
ormance. There was a statistically significantly higher mean
nd median activated clotting time post-protamine observed
n the off-pump prasugrel group. Concomitant medication
se within 5 days and 1 day of the CABG procedure
ncluded aspirin, unfractionated heparin, low-molecular-
eight heparin, direct thrombin inhibitors, and glyco-
rotein IIb/IIIa inhibitors, with no significant differences
etween the prasugrel and clopidogrel cohorts. At 5 days
Figure 2 Time From Randomization
to Isolated CABG Procedure
CABG  coronary artery bypass grafting; CL  confidence limit.hefore the procedure, the most commonly used concomitant
edication was aspirin (prasugrel 61%; clopidogrel 66%), as
as the case at 1 day before CABG (prasugrel 37%;
lopidogrel 41%).
In the isolated CABG cohort, 106 patients in the
rasugrel group and 126 patients in the clopidogrel group
aited 1 to 7 days off study drug before CABG (days from
ast dose to CABG for both groups are displayed in Table 2).
ithin this group, 4 patients in the clopidogrel group
xperienced non fatal MIs (3 on 1 day and 1 on 2 days after
he last dose of study drug). One of the MIs at 1 day after
he last dose of study drug was related to a definite or
robable stent thrombosis. There were no ischemic events
bserved in the prasugrel group who discontinued drug up
o 7 days awaiting surgery.
leeding and transfusions. Figure 3 illustrates individual
atient chest tube blood loss at 12 h. The data were highly
ariable, but there was a significantly higher overall mean
hest tube blood loss at 12 h in the prasugrel group
ompared with the clopidogrel group (655  580 ml [25th
ercentile 300 ml; 50th percentile 455 ml; 75th percentile
00 ml] vs. 503  378 ml [25th percentile 250 ml; 50th
ercentile 395 ml; 75th percentile 640 ml]; p  0.050).
here was no significant relationship between the duration
f study drug withdrawal and this difference between study
rugs. The incidence of platelet transfusion was significantly
Demographic Characteristics and Baseline TRITON–TIMI 38 Medical History for the Isolated CABG CohortTable 1 Demographic Char cteristics and Baseline TRITON–TIMI 38 Medical History for the Isolated CABG Cohort
Characteristic
Prasugrel
(n  173)
Clopidogrel
(n  173) p Value*
Demographic
Region of enrollment 0.821
North America 28 (16.2) 34 (19.7)
South America 6 (3.5) 8 (4.6)
Europe 108 (62.4) 106 (61.3)
Other† 31 (17.9) 25 (14.5)
Age (yrs) 61.1 9.3 60.9 10.2 0.856
Age (yrs) 60.0 (54.0–69.0) 62.0 (54.0–69.0)
Age 75 yrs 14 (8.1) 12 (6.9) 0.683
Male 130 (75.1) 135 (78.0) 0.526
Weight 60 kg 13 (7.7) 10 (5.9) 0.527
Medical history
Cerebrovascular
disease
14 (8.1) 13 (7.5) 0.841
Hypertension 115 (66.5) 107 (61.9) 0.370
Diabetes mellitus 51 (29.5) 47 (27.2) 0.633
TRITON baseline clinical
presentation
0.823
UA/NSTEMI 110 (63.6) 112 (64.7)
STEMI 63 (36.4) 61 (35.3)
Values are n (%), mean  SD, or median (25th–75th percentiles). *p values were calculated with
Pearson’s chi-square test (categorical variables) or analysis of variance (continuous variables).
†Africa, Asia, and the Mideast.
CABG  coronary artery bypass grafting; NSTEMI  non–ST-segment elevation myocardial
infarction; STEMI ST-segment elevation myocardial infarction; TRITON–TIMI 38 Trial to Assess
mprovement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–
hrombolysis In Myocardial Infarction; UA  unstable angina.igher in the prasugrel group compared with the clopidogrel
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Characteristic
Prasugrel
(n  173)
Clopidogrel
(n  173) p Value*
Preoperative characteristics
Heart failure 21 (12.2) 16 (9.3) 0.384
Ejection fraction 30% 2 (1.2) 8 (4.6) 0.062
UA requiring pre-CABG IV nitrates 20 (11.6) 17 (9.8) 0.602
Inotropic support 5 (2.9) 7 (4.1) 0.550
Peripheral vascular disease 13 (7.5) 11 (6.4) 0.672
Moderate to severe mitral valve regurgitation 6 (3.5) 8 (4.7) 0.601
MI within 24 h before CABG 6 (3.5) 8 (4.6) 0.585
PCI within 6 h of CABG 12 (6.9) 6 (3.5) 0.146
History of CV surgery 3 (1.7) 7 (4.1) 0.196
COPD 8 (4.6) 20 (11.6) 0.017
Procedural characteristics
CABG occurred during TRITON index event 8 (4.62) 7 (4.05) 0.792
CABG status (%) 0.931
Elective 84.4 85.0
Urgent 13.9 12.7
Emergent or salvage 1.7 2.3
Thoracotomy (%) 1.8 4.7 0.123
Intra-aortic balloon pump use (%) 7.6 11.8 0.194
On-pump (%) 75.0 86.0 0.010
Total cross-clamp time (min) 53 27 49 23
Total cross-clamp time (min) 46 (34-65) 47 (33-61) 0.500
Total heparin (U) during operation 33,012 19,177 34,500 19,700
Total heparin (U) during operation 33,250 (22,000–40,000) 32,000 (25,000–40,000) 0.861
Protamine (mg) 315 126 336 127
Protamine (mg) 300 (250–400) 325 (260–400) 0.232
ACT, highest recorded (s) 633 184 653 194
ACT, highest recorded (s) 604 (495–735) 617 (506–800) 0.538
ACT, post-protamine (s) 164 130 151 88
ACT, post-protamine (s) 130 (120–146) 127 (121–141) 0.301
Off-pump, % 25.0 14.0 0.010
Heparin (U) loading dose 14,022 8,678 15,444 9,112
Heparin (U) loading dose 13,750 (9,000–20,000) 10,000 (10,000–19,000) 0.938
Heparin (U) intraoperative 15,195 8,972 30,833 52,530
Heparin (U) intraoperative 13,500 (10,000–22,500) 15,000 (10,000–20,000) 0.726
Protamine (mg) 169 97 188 112
Protamine (mg) 150 (100–200) 150 (100–250) 0.683
ACT, post-protamine (s) 137 17 123 11
ACT, post-protamine (s) 137 (125–146) 124 (117–131) 0.018
No. of diseased vessels 0.371
1 26 (15.0) 24 (13.9)
2 108 (62.4) 105 (60.7)
3 36 (20.8) 35 (20.2)
Days from last dose to CABG 0.257
0 16 (9.2) 14 (8.1)
1 15 (8.7) 13 (7.5)
2 12 (6.9) 17 (9.8)
3 12 (6.9) 10 (5.8)
4 9 (5.2) 11 (6.4)
5 24 (13.9) 34 (19.7)
6 21 (12.1) 16 (9.2)
7 13 (7.5) 25 (14.5)
8–14 36 (20.8) 20 (11.6)
14 14 (8.1) 12 (6.9)
Unknown or missing 1 (0.6) 1 (0.6)
Values are n (%), mean SD, or median (25th–75th percentile). *p values were calculated by using Pearson’s chi-square test (categorical variables)
or Kruskal-Wallis test (continuous variables).ACT activated clotting time; COPD chronic obstructive pulmonary disease; CV cardiovascular; IV intravenous; MImyocardial infarction;
PCI  percutaneous coronary intervention; other abbreviations as in Table 1.
i
g
p
P
t
a
p
e
E
d
1
t
d
393JACC Vol. 60, No. 5, 2012 Smith et al.
July 31, 2012:388–96 The TRITON–TIMI 38 CABG Cohortgroup (17.96% vs. 9.82%; p  0.033) as was the mean
number of platelet units transfused (0.78 U vs. 0.39 U; p 
0.047). However, there was no significant difference in
packed red blood cell transfusion (2.1 U vs. 1.7 U; p 
0.442) or the total donor exposure (packed red blood cell 
whole blood  platelets  cryoprecipitate  fresh-frozen
plasma) between the prasugrel and clopidogrel groups (4.4
U vs. 3.0 U; p  0.463). There was a trend toward a higher
incidence of surgical re-exploration for bleeding in the
prasugrel group (n  11 [surgical source of bleeding
dentified in 8 patients]) compared with the clopidogrel
roup (n  4 [surgical source of bleeding identified in 3
atients]).
ost-operative status. There was no difference in hospi-
al length of stay between cohorts. Table 3 reports details
of the postoperative period and hospital readmission post-
CABG.
Figure 3 Chest Tube Loss at 12 h by Days
From Last Dose of Study Drug to CABG
Individual patient chest tube blood loss is indicated by patient in each treat-
ment group. The solid line indicates the median blood loss (420 ml). CABG 
coronary artery bypass grafting.
Post-Operative Outcomes for the Isolated CABGTable 3 Post-Operative Outcomes for the Is
Outcome
Post-operative (in hospital), n (%)
Deep sternal infection
Respiratory dysfunction (vent 24 h)
Readmission within 30 days of CABG discharge, n (%)
Readmission to hospital within 30 days
Readmission to hospital for deep sternal infection
Readmission to hospital for other infection
DAPT after CABG, n (deaths)
Resumed DAPT (open-label or study drug) after CABG
Study drug
Open-label clopidogrel
Did not resume DAPT (open-label or study drug) after C
Status unknownValues are n (%). *p values were calculated by using Pearson’s chi-square te
CABG  coronary artery bypass grafting; DAPT  dual antiplatelet therapyMortality. The mean EuroSCORE was 3.32  2.9 and
3.62  3.2, and the mean predicted probability of mortality
ccording to EuroSCORE was 0.04  0.06 and 0.05 
0.09, in the prasugrel and clopidogrel cohorts, respectively.
The mean predicted probability of mortality according to
the STS score was 0.01  0.03 and 0.02  0.04 in the
rasugrel and clopidogrel cohorts. Figure 4 depicts the fold
levation in predicted risk score as assessed by using the
uroSCORE for each patient by day from last dose of study
rug to isolated CABG procedure. Mortality was similar (3 of
6 prasugrel-treated patients; 3 of 14 clopidogrel-treated pa-
ients) when CABG was performed on the same day as last
ose of study drug. These patients were at a higher predicted
Figure 4
Fold Elevation of Predicted Risk of Mortality
Based on EuroSCORE by Days From Last Dose
of Study Drug to Isolated CABG Procedure
Individual patient elevation in predicted risk of mortality values by treatment
group are indicated. Patient values indicated with an X are observed mortality
in each treatment group. Zero is median risk for the population. Fold elevation
of predicted risk of mortality refers to the predicted probability of death for a
patient/median predicted probability for the entire group. CABG  coronary
artery bypass grafting; EuroSCORE  European System for Cardiac Operative
Risk Evaluation score.
ortd CABG Cohort
Prasugrel
(n  173)
Clopidogrel
(n  173) p Value*
1 (0.6) 4 (2.3) 0.215
10 (5.8) 9 (5.2) 0.824
12 (6.9) 15 (8.7) 0.537
0 (0.0) 3 (4.0) 0.082
2 (2.8) 6 (8.1) 0.276
129 (1) 122 (7)
108 (0) 106 (3)
21 (1) 16 (4)
44 (3) 49 (7)
0 (0) 2 (1)Coholate
ABG†st or Fisher exact test. †All deaths occurred in hospital.
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study drug was discontinued for 1 day, mortality was
lower with prasugrel (1 of 156 prasugrel-treated patients; 12
of 158 clopidogrel-treated patients). There were no deaths
in the 72 prasugrel-treated patients having CABG within 1
to 5 days of drug withdrawal and 6 deaths in the 85
clopidogrel-treated patients having CABG under the same
conditions.
All-cause mortality was 2.31% in the prasugrel cohort
compared with 8.67% in the clopidogrel cohort (adjusted
odds ratio [OR]: 0.26 [95% confidence interval (CI): 0.08 to
0.85]; p 0.025). The mortality rate at 30 days adjusted for
imbalances at baseline, when analyzed by using logistic
regression per EuroSCORE, remained statistically signifi-
cant (adjusted OR: 0.17 [95% CI: 0.04 to 0.79]; p 0.024).
Similar results were observed when mortality was adjusted
for STS mortality risk score. CV death within 30 days after
CABG was 0.58% for the prasugrel cohort compared with
5.78% for the clopidogrel cohort (OR: 0.11 [95% CI: 0.01
to 0.84]; p  0.034). Overall CV death was 1.73% for the
rasugrel cohort compared to 6.94% for the clopidogrel
ohort (OR: 0.25 [95% CI: 0.07 to 0.98]; p  0.047). A
aplan-Meier curve of the cumulative incidence of all-cause
eath for the prasugrel and clopidogrel isolated CABG
roups is illustrated in Figure 5. There was a statistically
ignificantly lower risk of mortality in the prasugrel group
ompared with the clopidogrel group before and after
djustment for baseline differences with predicted Euro-
CORE mortality risk. In-hospital mortality rate for pra-
ugrel and clopidogrel was 3 of 173 patients and 8 of 173
atients, respectively. The mortality benefit observed in the
rasugrel cohort seemed to be similar regardless of whether
Figure 5 KM Estimate of the Cumulative Incidence of
All-Cause Death Across Time From Isolated CABG
The 30-day time point is indicated by the dashed line. The 30-day all-cause
mortality rate for prasugrel was 1.16% versus 6.94% for clopidogrel. KM 
Kaplan-Meier; other abbreviations as in Figure 2.fiual antiplatelet therapy treatment was resumed after the
ABG procedure (Table 3).
iscussion
urrent American College of Cardiology/American Heart
ssociation guidelines recommend the early use of adeno-
ine diphosphate receptor P2Y12 inhibitors in patients with
CS in whom PCI is anticipated (17,18). The guidelines
lso recommend delaying elective CABG for 5 days after
he last dose of clopidogrel and 7 days after the last dose of
rasugrel, if possible (18). However, these guidelines are
ased on consensus opinions, and there are concerns that a
elay of CABG to reduce bleeding risk may come at the
xpense of increased risk of myocardial injury/MI and/or
tent thrombosis while awaiting surgery (19). Concern
bout CABG-related bleeding and difficulty in accurately
dentifying which patients will require CABG potentially
imits early initiation of platelet inhibition along with the
otential benefits of thienopyridines in non–ST-segment
levation MI ACS (20). This retrospective analysis of the
atients undergoing CABG in the TRITON–TIMI 38 trial
s the first characterization of outcomes in patients receiving
rasugrel followed by a CABG procedure, and provides
nformation about the relationship between residual anti-
latelet drug activity, perioperative bleeding, and mortality.
verall, this study supports the perception that an increase
n residual antiplatelet drug effect increases bleeding and
ransfusion; however, an increase in residual antiplatelet
ffect was also shown to be associated with a reduction of
ortality hazard in patients treated with prasugrel com-
ared with clopidogrel. Multivariate analyses and standard
ortality risk-adjustment methods indicate that this differ-
nce is not related to any other potential confounders.
This finding of increased bleeding is also consistent with
ther studies of antiplatelet agents in which CABG was
afely performed during periods of drug effect, presumably
or clinical indications obviating surgical delay. Both abcix-
mab (21) and clopidogrel (22) have been shown to have
ncreased bleeding and transfusion outcomes compared with
spirin alone, whereas ticagrelor had similar bleeding and
ransfusion rates compared with clopidogrel (23). The
bservation of increased bleeding, transfusion, and re-
xploration observed with the use of prasugrel in patients
ho require surgical intervention is an important finding for
linicians who are managing these patients in the perioper-
tive setting. A better understanding of the bleeding risk
ill allow clinicians to be ready with respect to the potential
or volume resuscitation, platelet therapy, or other hemo-
tatic therapy for those patients who develop life-
hreatening bleeding after cardiac surgery.
Similar to prasugrel in the current study, abciximab (21)
nd ticagrelor (7) have been associated with improved
ABG survival versus the comparator. As with these 2
gents, the survival differences are noted primarily in the
rst 30 days, suggesting that perioperative events related to
395JACC Vol. 60, No. 5, 2012 Smith et al.
July 31, 2012:388–96 The TRITON–TIMI 38 CABG Cohortsurgery are affected by residual and continued antiplatelet
therapy. The specific mechanism for this survival advantage
was unclear for either abciximab or ticagrelor, and the event
rates in the current study for other ischemic endpoints and
infection endpoints were too small to add understanding
given the sample size of this study. This is the first study, to
the best of our knowledge, to use standard risk-adjustment
methods to confirm that the comparative risk is not related
to other potential confounding factors.
Study limitations. First, this study was a retrospective
analysis involving patients who were randomized to receive
either clopidogrel or prasugrel before an indication for
CABG emerged. In this setting, there are possible unknown
confounders influencing the baseline risk of CABG that
differ between the study arms and may not be corrected for
by the methods used. For example, the incidence of COPD
and off-pump CABG performance differed between study
groups despite investigator blinding to the study drug. The
presence of COPD is an incorporated risk factor in the STS
and EuroSCORE algorithms but the utilization of cardio-
pulmonary bypass could not be adjusted for with these tools.
Postoperative bleeding is known to be affected by cardio-
pulmonary bypass and will be further explored, but mortality
outcome is not similarly affected. Second, the decision to
perform CABG and factors related to the timing of CABG
are unknown and were therefore not characterized in this
analysis. This decision, combined with the relatively small
number of patients in various states of study drug “washout,”
makes these data difficult to translate into definitive recom-
mendations regarding optimal decision making. In addition,
small subgroup size limits the statistical power associated
with comparisons between prasugrel and clopidogrel, and
the imputation of missing values may potentially limit the
risk-adjustment. Finally, the study design of the parent
randomized trial, with the stated goal of PCI that was based
on knowledge of the coronary anatomy before randomiza-
tion, resulted in a CABG population enriched with 1- and
2-vessel coronary artery disease. Thus, the results are less
generalizable to the typical population of patients referred
for bypass surgery in whom 3-vessel disease predominates or
in patients who undergo complex or multiple operative
procedures. Despite these limitations, this study provides
important additional information to surgeons and cardiol-
ogists as they determine the appropriate antiplatelet agent to
enhance outcomes after PCI, and the impact on overall
patient outcome if CABG is eventually selected as the
desired revascularization strategy.
Conclusions
The analysis focused on patients receiving isolated CABG
(CABG with no additional procedures), the majority of
patients in the trial. The prasugrel cohort had a statistically
significantly higher chest tube blood loss as well as a
significantly higher use of platelets. This analysis suggests
that there may be an increased need for surgical re-exploration in prasugrel-treated patients, which is consistent
with the significant differences noted in the bleeding and
transfusion parameters. The mortality observed in patients
with high chest tube blood loss and increased transfusion
requirements was associated with a high predicted risk of
mortality before CABG (24). Patients who had lower
predicted mortality risk did not have a subsequently in-
creased mortality associated with higher chest tube blood
loss or increased transfusion requirements. For all patients,
the lower mortality rate in the prasugrel cohort overall and
at 30 days persisted after risk adjustment using the Euro-
SCORE or the STS score. Despite an increase in observed
bleeding, platelet transfusion, and surgical re-exploration for
bleeding, patients treated with prasugrel before isolated
CABG were observed to have a mortality rate that was
significantly lower than patients administered clopidogrel
before undergoing CABG while enrolled in the TRITON–
TIMI 38 study.
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